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Q Which nonhormonal treatments 
are effective for hot flashes?
 Selective serotonin reuptake 
 inhibitors (SSRIs [fluoxetine, 
sertraline, paroxetine]) and the selec-
tive norepinephrine reuptake inhibitor 
(SNRI) venlafaxine, as well as clonidine 
and gabapentin, reduce hot flashes by 
about 25% (approximately one per day) 
in women with and without a history of 
breast cancer. No studies compare medi-
cations against each other to determine 
a single best option (strength of recom-
mendation [SOR]: A, systematic reviews 
and meta-analyses of randomized con-
trolled trials [RCTs]). In comparison, 
estrogen reduces the frequency of hot 
flashes by about 75%, or 2.5 to 3 per day. 
The phytoestrogens (soy isofla-
vones, red clover extract, black cohosh), 
vitamin E, and nonpharmacologic mea-
sures (relaxation therapy, exercise, acu-
puncture, homeopathy, magnet therapy) 
lack evidence of effectiveness (SOR: A, me-
ta-analyses of RCTs, many of which were 
low quality).
Evidence summary
A systematic review of 6 RCTs that evaluated 
SSRIs and SNRIs (fluoxetine, sertraline, par-
oxetine, venlafaxine) found them all to be ef-
fective for reducing hot flash frequency and 
symptom scores in women with previous 
breast cancer1 (TABLE1,2). 
A 2006 meta-analysis combined the 
results of 7 RCTs (each evaluating a sin-
gle SSRI [fluoxetine, paroxetine] or SNRI 
[venlafaxine]) and found that as a group, 
they reduced mean hot flash frequency 
(–1.13 hot flashes/d; 95% confidence interval 
[CI], –1.70 to –0.57) in women with and with- 
out breast cancer.2 No trial compared medi-
cations head to head, and the populations 
differed among studies, so that investigators 
couldn’t determine a single best agent.
Clonidine and gabapentin  
decrease hot flash frequency
The 2006 meta-analysis also included 
10 RCTs (743 patients) that studied cloni-
dine in women with and without a history of 
breast cancer, and 2 RCTs (479 patients) that 
evaluated gabapentin in women with breast 
cancer.2 Both drugs reduced mean hot flash 
frequency (clonidine: –0.95 hot flashes/d, 
95% CI, –1.44 to –0.47 at 4 weeks and –1.63 hot 
flashes/d, 95% CI, –2.76 to –0.05 at 8 weeks; 
gabapentin: –2.05 hot flashes/d; 95% CI, 
−2.80 to –1.30).
Phytoestrogens: The jury is still out
A meta-analysis of 43 RCTs (4364 patients) 
evaluated phytoestrogens that included di-
etary soy, soy extracts, red clover extracts, 
genistein extracts, and other types of phy-
toestrogens.3 The data from the only 5 RCTs 
(300 patients) that could be combined 
showed no effect from red clover extract on 
hot flash frequency. However, another 4 in-
dividual trials that couldn’t be combined 
each found that extracts with high levels of 
the phytoestrogen genistein (>30 mg/d) did 
reduce frequency. Investigators reported that 
many of the trials were small and had a high 
risk of bias. 
A meta-analysis of 16 RCTs (2027 pa-
tients) that assessed black cohosh found that 
it didn’t reduce hot flash frequency (3 RCTs, 
393 patients) or symptom severity scores 
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(4 RCTs, 357 patients).4 Investigators reported 
high heterogeneity and recommended fur-
ther research. 
Nonpharmacologic therapies  
and vitamin E don’t help
Systematic reviews found that relaxation 
therapy (4 RCTs, 281 patients), exercise 
(3 RCTs, 454 patients), and acupuncture 
(8 RCTs, 414 patients) didn’t reduce hot 
flashes.5-7 In another review, vitamin E 
(1 RCT, 105 patients), homeopathy (2 RCTs, 
124 patients), and magnetic devices (1 RCT, 
11 patients) also produced no benefit.1             JFP
TABLE
Nonhormonal treatments for hot flashes: The evidence for their efficacy
Medication (dose) RCT  
duration 
(wk)
Population Hot flash outcomes  
(intervention vs  
placebo)
Notes Withdrawal % (adverse 
effects causing  
withdrawal) 
Clonidine1,2  
(0.1 mg/d)
8 198 women with 1 or 
more hot flashes daily 
(all with breast cancer 
and using tamoxifen)
Reduced frequency: 
38% vs 24%; P=.006
Reduced hot flash  
duration: 22% decrease 
vs 17% increase; P=.02
45% (difficulty 
sleeping) 
Clonidine  
transdermal1,2 
(0.1 mg/d)
4 116 women with 7 or 
more hot flashes weekly 
(all with breast cancer 
and using tamoxifen)
Reduced frequency: 
44% vs 27%; P<.04
Reduced composite 
symptom score: 56% vs 
30%; P<.04
No withdrawals for 
adverse effects, 
although there were 
reports of dry mouth, 
constipation,  
drowsiness
Fluoxetine2  
(20 mg/d, increased 
to 30 mg/d at 6 mo)
Citalopram2  
(20 mg/d, increased 
to 30 mg/d at 6 mo)
38 150 women with 
symptoms after natural 
menopause
Reduced frequency: 
58%-64% of women 
reported >50% 
reduction in hot flashes; 
P<.01
Study didn’t 
report  
differences 
between 
fluoxetine and 
citalopram
20% (nausea and dry 
mouth; 1 case of  
pulmonary embolism 
in the citalopram 
group)
Gabapentin2  
(100 mg tid and 300 
mg tid)
8 420 women with 2 or 
more hot flashes daily, 
all with breast cancer 
and 71% using  
tamoxifen; mean 
age 55 yr
Reduced frequency: 
44% vs 15%; P<.001
Reduced severity: 
46% vs 15%; P<.001
Reductions only 
significant for 
900 mg/d dose
10% (somnolence,  
fatigue)
Gabapentin2  
(300 mg tid)
12 59 women with 7 or 
more hot flashes/d; 
mean age, 53 yr
Reduced frequency: 
45% vs 22%; P=.02
Reduced composite 
symptom score: 54% vs 
31%; P=.01
14% (dizziness, rash, 
palpitations, edema)
Paroxetine1,2  
(10-20 mg/d)
3 151 women with 14 or 
more hot flashes weekly 
(>80% with breast  
cancer, >60% on  
tamoxifen)
Reduced frequency: 
50.5% vs 16%; P<.001
Reduced composite 
symptom score: 54% vs 
19%; P<.001
Outcomes same 
for both doses 
of paroxetine
22% (drowsiness, 
nausea)
Paroxetine CR2 
(12.5 or 25 mg/d) 
6 165 women with 14 or 
more hot flashes weekly 
(7% with breast cancer, 
7% on tamoxifen or 
raloxifene)
Reduced frequency:  
3.25 vs 1.8 fewer/d; 
P=.01
Reduced composite 
symptom score: 63.5% 
vs 38%; P=.03
Outcomes same 
for both doses 
of paroxetine 
CR
17% (headache,  
nausea, insomnia)
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TABLE
Nonhormonal treatments for hot flashes: The evidence for their efficacy (cont’d)
Medication (dose) RCT 
duration 
(wk)
Population Hot flash outcomes  
(intervention vs  
placebo)
Notes Withdrawal % (adverse 
effects causing  
withdrawal)
Sertraline1  
(50 mg/d) 
6 62 women with daily 
hot flashes (all with 
history of breast cancer) 
Reduced frequency: 
0.9 fewer vs 1.5 more; 
P=.03
Reduced symptom 
score: 15% vs 30% 
increase; P=.03
Study  
underpowered, 
23 participants 
completed
Venlafaxine1 
(37.5, 75 mg/d)
6 68 women with 6 or 
more hot flashes/d (all 
with history of breast 
cancer)
Reduced frequency: 
42% vs 18% (37.5 mg); 
P<.001; 25% vs 4%  
(75 mg); P<.001 
Reduced symptom 
score: 7% vs 6% 
increase; P<.001 (37.5 
mg); 27% vs 5%; P<.001 
(75 mg)
40% of  
participants 
didn’t provide 
data; results 
calculated by 
intention to 
treat
Venlafaxine XR1,2  
(37.5, 75, or 150 
mg/d)
4 221 women with 14 or 
more hot flashes weekly 
(all with breast cancer 
or at high risk for breast 
cancer)
Reduced frequency: 
30% (37.5 mg), 46% 
(75 mg), 58% (150 
mg) vs 19% (placebo); 
P<.001
Reduced composite 
symptom score 37%-
61% vs 27%; P<.001
Greatest effect 
with the 2 
higher doses
27% (dry mouth, 
decreased appetite, 
nausea, constipation 
[most often at high 
doses])
Venlafaxine XR2  
(75 mg/d)
12 80 women with 14 or 
more hot flashes weekly
No difference in hot 
flash frequency or 
severity 
Reduced perceived 
hot flash score: 51% vs 
15%; P<.001 
 48% (dry mouth,  
sleeplessness,  
decreased appetite)
RCT, randomized controlled trial.
